1Ikawa S,Fukui M,Ueyama Y,et al. B-raf,a new member of the raf family,is activated by DNA rearrangement [ J ]. Mol Cell Biol, 1988,8(6) :2651-2654.
2MacCorkle RA,Tan TH. Mitogen-activated protein kinases in cell-cycle control [ J ]. Cell Biochem Biophys ,2005,43 ( 3 ) :451 - 461.
3Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy [J]. Ann Med,2006,38(3) :200-211.
4Davies H,Bignell GP,,Cox C ,etal. Muta- tions of the BRAF gene in human cancer [ J ]. Nature ,2002,417 ( 6892 ) :949-954.
5Xing M,Tufano RP,Tufaro AP, et al. De- tection of BRAF mutation on fine needle aspiration biopsy specimens: a new diag- nostic tool for papillary thyroid cancer [J]. J Clin Endoerinol Metab, 2004,89 (6) :2867-2872.
8Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[ J]. J Clin Endocrinol Metab, 2005,90 ( 12 ) : 6373-6379.
9Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E muta- tion and mortality in patients with papilla- ry thyroid cancer BRAF V600E mutation in papillary thyroid cancer [ J ]. JAMA, 2013,309( 14 ) :1493-1501.
3Leenhardt L,Grosclaude P,Cherie-Challine L,et al.Increased incidence of thyroid carcinoma in France:a true epidemic or thyroid nodule management effects? Report from the French thyroid cancer committee.Thyroid,2004,14:1056-1060.
4Davies L,Welch HG.Increasing incidence of thyroid cancer in the United States.JAMA,2006,295:2164-2167.
5Hundahl SA,Fleming ID,Fremgen AM,et al.A national cancer data base report on 53 856 cases of thyroid carcinoma treated in the US.Cancer,1998,83:2638-2648.
6Dohan O,Baloch Z,Banrevi Z,et al.Rapid communication:predominant intracellular over expression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases.J Clin Endocrinol Metab,2001,86:2697-2700.
7Nikiforova MN,Kimura ET,Gandhi M,et al.BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.J Clin Endocrinol Metab,2003,88:5399-5404.
8Frattini M,Ferrario C,Bressan P,et al.Alternative mutations of BRAF,RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.Oncogene,2004,23:7436-7440.
9Kimura ET,Nikiforova MN,Zhu Z,et al.High prevalence of BRAF mutations in thyroid cancer:genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.Cancer Res,2003,63:1454-1457.
10Xing MZ,Westra WH,Tufano RP,et al.BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.J Clin Endocrinol Metab,2005,90:6373-6379.
